← Back to Search

Synthetic Tissue Substitute

Synthetic Tissue Substitute for Ocular Implant Concealment (EverPatch Trial)

N/A
Waitlist Available
Research Sponsored by CorNeat Vision Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged ≥ 18 and ≤ 80 years on screening day
Patients with viable and intact conjunctiva
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 & 12 months post-op.
Awards & highlights

EverPatch Trial Summary

This trial will test how safe and effective a new device is at hiding artificial ocular implants.

Who is the study for?
Adults aged 18-80 needing concealment of glaucoma tube shunts or suture tags, with healthy conjunctiva and adequate tear film. Participants must be able to consent, follow the study plan, have light perception vision or better, and use contraception if applicable. Excluded are those with retinal detachment, infections, severe eye diseases within 6 months, ocular malignancy history, keloid formation tendency, material hypersensitivity (specifically listed substances), life expectancy under a year due to severe disease.Check my eligibility
What is being tested?
The trial is evaluating the CorNeat EverPatch device as a synthetic tissue substitute for hiding artificial ocular implants in patients with tissue necrosis or glaucoma. The safety and performance of this new medical device will be closely monitored throughout the study.See study design
What are the potential side effects?
Potential side effects may include local reactions at the implant site such as irritation or inflammation; allergic responses to materials in the EverPatch; infection risks; and possibly interference with vision depending on individual healing processes.

EverPatch Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 80 years old.
Select...
My eye's outer membrane is healthy and undamaged.

EverPatch Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 & 12 months post-op.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 & 12 months post-op. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety Assessment
Secondary outcome measures
Performance Assessment

EverPatch Trial Design

1Treatment groups
Experimental Treatment
Group I: Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic ImplantsExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

CorNeat Vision Ltd.Lead Sponsor
3 Previous Clinical Trials
78 Total Patients Enrolled
1 Trials studying Glaucoma
28 Patients Enrolled for Glaucoma

Media Library

CorNeat EverPatch (Synthetic Tissue Substitute) Clinical Trial Eligibility Overview. Trial Name: NCT05469867 — N/A
Glaucoma Research Study Groups: Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
Glaucoma Clinical Trial 2023: CorNeat EverPatch Highlights & Side Effects. Trial Name: NCT05469867 — N/A
CorNeat EverPatch (Synthetic Tissue Substitute) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05469867 — N/A
Glaucoma Patient Testimony for trial: Trial Name: NCT05469867 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people able to currently enroll in this research?

"According to the information provided by clinicaltrials.gov, this trial is not in a recruitment phase at present. The post was first made on August 1st 2022 and its most recent revision happened on July 19th 2022. Albeit inactive, there are 206 other trials actively enrolling patients right now."

Answered by AI

Is the protocol for this experiment including individuals who are beyond middle-age?

"This clinical trial stipulates that patients must be aged between 18 and 80 years old. In addition, there are 23 studies for minors under the age of 18 and 191 opportunities available to those who exceed 65 years of seniority."

Answered by AI

What type of individual would be the best candidate for this experiment?

"To be eligible for this study, subjects must have a glaucoma diagnosis and fall between the ages of 18 to 80. Sixty participants are needed in total."

Answered by AI

Who else is applying?

What site did they apply to?
EyeCare Miramichi Eye NB
University Health Network
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0
3+

Why did patients apply to this trial?

I want to recover my sight. I have been diagnosed with glaucoma for the past 4years and I would like to make treatment to improve my sight.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Pivotal Trial for a Synthetic Tissue Substitute for Concealment of Artificial Ocular Implants
2022. "Pivotal Trial for a Synthetic Tissue Substitute for Concealment of Artificial Ocular Implants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05469867.
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top